Cargando…
Sample‐size estimation is not reported in 24% of randomised controlled trials of inflammatory bowel disease: A systematic review
BACKGROUND: Sample‐size estimation is an important factor in designing a clinical trial. A recent study found that 65% of Cochrane systematic reviews had imprecise results. OBJECTIVE: This study set out to review the whole body of inflammatory bowel disease (IBD) randomised controlled trials systema...
Autores principales: | Iheozor‐Ejiofor, Zipporah, Lakunina, Svetlana, Gordon, Morris, Akintelure, Daniel, Sinopoulou, Vasiliki, Akobeng, Anthony |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259284/ https://www.ncbi.nlm.nih.gov/pubmed/33104495 http://dx.doi.org/10.1177/2050640620967899 |
Ejemplares similares
-
Minimum sample size estimates for trials in inflammatory bowel disease: A systematic review of a support resource
por: Gordon, Morris, et al.
Publicado: (2021) -
BSG 2024 IBD guidelines protocol (standard operating procedures)
por: Gordon, Morris, et al.
Publicado: (2023) -
Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial
por: Zoller, Heinz, et al.
Publicado: (2023) -
Subclinical bowel inflammation increases healthcare resources utilization and steroid use before diagnosis of inflammatory bowel disease
por: Rodríguez‐Lago, Iago, et al.
Publicado: (2022) -
Changing paradigms in management of inflammatory bowel disease
por: Mao, Ren, et al.
Publicado: (2022)